{"altmetric_id":13869945,"counts":{"readers":{"mendeley":8,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:14546023"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa50c3cf058f610003194","authors":["Neggers SJ","Muhammad A","van der Lelij AJ"],"doi":"10.1159\/000381644","endpage":"65","first_seen_on":"2016-11-21T20:48:55+00:00","issns":["0028-3835","1423-0194"],"issue":"1","journal":"Neuroendocrinology","last_mentioned_on":1479761332,"links":["https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25792221"],"pmid":"25792221","pubdate":"2015-03-19T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Neurosciences","scheme":"era"}],"scopus_subjects":["Life Sciences","Medicine","Health Sciences","Neuroscience","Biochemistry, Genetics and Molecular Biology"],"startpage":"59","subjects":["endocrinology","neurology"],"title":"Pegvisomant Treatment in Acromegaly","type":"article","volume":"103","mendeley_url":"http:\/\/www.mendeley.com\/research\/pegvisomant-treatment-acromegaly"},"altmetric_score":{"score":3,"score_history":{"1y":3,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":7722526,"mean":6.6240776217551,"rank":1882201,"this_scored_higher_than_pct":62,"this_scored_higher_than":4813521,"rank_type":"exact","sample_size":7722526,"percentile":62},"similar_age_3m":{"total_number_of_other_articles":247221,"mean":12.202472016827,"rank":83764,"this_scored_higher_than_pct":64,"this_scored_higher_than":159994,"rank_type":"exact","sample_size":247221,"percentile":64},"this_journal":{"total_number_of_other_articles":303,"mean":2.0465894039735,"rank":34,"this_scored_higher_than_pct":62,"this_scored_higher_than":190,"rank_type":"exact","sample_size":303,"percentile":62},"similar_age_this_journal_3m":{"total_number_of_other_articles":5,"mean":0.9625,"rank":1,"this_scored_higher_than_pct":80,"this_scored_higher_than":4,"rank_type":"exact","sample_size":5,"percentile":80}}},"demographics":{"users":{"mendeley":{"by_status":{"Researcher":2,"Student  > Ph. D. Student":2,"Other":1,"Student  > Master":1,"Student  > Bachelor":1,"Unspecified":1},"by_discipline":{"Social Sciences":1,"Agricultural and Biological Sciences":1,"Biochemistry, Genetics and Molecular Biology":2,"Unspecified":2,"Pharmacology, Toxicology and Pharmaceutical Science":2}}},"geo":{"mendeley":{"DE":1}}},"posts":{"wikipedia":[{"title":"Pegvisomant","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=750787550#altmetric_citation_6e6e4a82-fd5f-4461-a3dc-5f830a86b183","license":"public","citation_ids":[13869945,13869945],"posted_on":"2016-11-21T20:48:52+00:00","summary":"Pegvisomant (trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly.","page_url":"http:\/\/en.wikipedia.org\/?curid=14546023","wiki_lang":"en","author":{"name":"Chris Capoccia","url":"http:\/\/en.wikipedia.org\/wiki\/User:Chris Capoccia"}}]}}